<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>GLP-1 on DEX Research</title><link>https://thedexs.com/tags/glp-1/</link><description>Recent content in GLP-1 on DEX Research</description><generator>Hugo -- gohugo.io</generator><language>en</language><lastBuildDate>Wed, 21 Oct 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://thedexs.com/tags/glp-1/index.xml" rel="self" type="application/rss+xml"/><item><title>Therapeutic Peptides and the GLP-1 Value Chain</title><link>https://thedexs.com/post/glp1-peptides/</link><pubDate>Wed, 21 Oct 2026 00:00:00 +0000</pubDate><guid>https://thedexs.com/post/glp1-peptides/</guid><description>&lt;img src="https://thedexs.com/post/glp1-peptides/assets/cover-original.jpg" alt="Featured image of post Therapeutic Peptides and the GLP-1 Value Chain" /&gt;&lt;style&gt;.main-article .article-header[data-article-url="https://thedexs.com/post/glp1-peptides/"] .article-image img{width:100%;height:auto;aspect-ratio:16/9;object-fit:cover;object-position:50% 54%}.article-content .glp1-cover{width:100%;margin:2rem 0}.article-content .glp1-cover img{display:block;width:100%;height:auto;aspect-ratio:16/9;object-fit:cover;object-position:50% 54%;border-radius:12px}.article-content figure[id^="research-table-glp1-"] .research-data-table{min-width:700px}.article-content figure[id^="research-table-glp1-"] .research-table-scroll-hint{display:block}&lt;/style&gt;
&lt;p class="research-preview-note"&gt;Industry report · Version 1.0 · Global scope · Research cutoff: 21 October 2026.&lt;/p&gt;
&lt;p class="research-figure-caption" id="cover-caption"&gt;Automated sample handling in a research laboratory. Illustrative image; not a GLP-1 manufacturing site. Photo: &lt;a href="https://unsplash.com/photos/laboratory-needles-dispensing-into-vials-2fyeLhUeYpg"&gt;National Cancer Institute / Unsplash&lt;/a&gt;, used under the &lt;a href="https://unsplash.com/license"&gt;Unsplash License&lt;/a&gt;. &lt;a href="assets/cover-original.jpg"&gt;View uncropped original&lt;/a&gt;.&lt;/p&gt;
&lt;p class="research-downloads"&gt;&lt;a href="assets/DEX-GLP1-Industry-Report-Bilingual-v1.0.docx" download&gt;Bilingual review report (Word)&lt;/a&gt; · &lt;a href="assets/DEX-GLP1-Industry-Report-Bilingual-v1.0.pdf" download&gt;Bilingual review report (PDF)&lt;/a&gt; · &lt;a href="assets/report-en.txt" download&gt;English manuscript&lt;/a&gt; · &lt;a href="assets/supporting-evidence-en.json" download&gt;Evidence records&lt;/a&gt;&lt;/p&gt;
&lt;p class="research-figure-caption"&gt;The downloadable bilingual review files retain their earlier AI-concept cover. This published website edition uses the credited laboratory photograph above; the research text is unchanged.&lt;/p&gt;
&lt;p&gt;Version 1.0 | Global scope with attention to the Chinese supply chain | Research cutoff: 21 October 2026. Annual, moving-annual-total and half-year observations are labelled separately. “Biological peptides” here means therapeutic peptides and their pharmaceutical supply chain, excluding food, cosmetic, collagen-hydrolysate and unapproved wellness-peptide markets. The GLP-1 scope includes single-receptor agonists and dual/multiple agonists with GLP-1 activity. Non-peptide GLP-1 medicines are discussed only as competitive substitutes. This is industry research, not medical, prescribing or investment advice.&lt;/p&gt;
&lt;h2 id="part-1-industry-story"&gt;&lt;a href="#part-1-industry-story" class="header-anchor"&gt;&lt;/a&gt;Part 1: Industry Story
&lt;/h2&gt;&lt;h3 id="1-three-factories-explain-more-than-one-injection"&gt;&lt;a href="#1-three-factories-explain-more-than-one-injection" class="header-anchor"&gt;&lt;/a&gt;1. Three factories explain more than one injection
&lt;/h3&gt;&lt;p&gt;On 18 December 2024, Novo Nordisk completed the acquisition of three manufacturing sites from Novo Holdings. The parties matter: Novo Holdings acquired Catalent; Novo Nordisk acquired three of its fill-finish sites. In June 2026, Catalent was still correcting reports that incorrectly treated the Bloomington facility, now owned and operated by Novo Nordisk, as part of its own network. &lt;a class="evidence-cite" href="#source-E01" aria-label="Source E01"&gt;[E01]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-E02" aria-label="Source E02"&gt;[E02]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Why would a company with successful medicines compete for filling plants? An approved molecule must still become a formulated, aseptically filled, tested, released and distributed product. A slow expansion at any of these stages can prevent upstream synthesis capacity from becoming sales. The acquisition does not establish a site&amp;#x27;s GLP-1 output, but it demonstrates the strategic importance of controlling downstream manufacturing.&lt;/p&gt;
&lt;p&gt;On 21 February 2025, the US FDA determined that the national semaglutide-injection shortage was resolved while acknowledging possible local interruptions. &lt;a class="evidence-cite" href="#source-E03" aria-label="Source E03"&gt;[E03]&lt;/a&gt; Aggregate supply and a patient&amp;#x27;s ability to obtain one presentation at one pharmacy are different problems. The commercial challenge extends from making a molecule to supporting continuous, compliant and affordable care.&lt;/p&gt;
&lt;h3 id="2-separate-three-markets-before-counting-them"&gt;&lt;a href="#2-separate-three-markets-before-counting-them" class="header-anchor"&gt;&lt;/a&gt;2. Separate three markets before counting them
&lt;/h3&gt;&lt;p&gt;Therapeutic peptides are medicines with peptide active ingredients and the manufacturing services behind them; GLP-1 is an important subset. GLP-1-related medicines are a mechanism-based category that can include both peptides and non-peptide small molecules. Obesity medicines are an indication-based category. The same molecule can appear in different brands, formulations and indications. These categories overlap without being interchangeable.&lt;/p&gt;
&lt;p&gt;The distinction has immediate commercial consequences in 2026. US approval of oral Wegovy demonstrates that oral delivery does not mean a non-peptide molecule. Foundayo (orforglipron), by contrast, is an approved non-peptide oral GLP-1 medicine: it may compete for patients without creating the same peptide-input demand. &lt;a class="evidence-cite" href="#source-M03" aria-label="Source M03"&gt;[M03]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-M04" aria-label="Source M04"&gt;[M04]&lt;/a&gt; Authorisations remain product-, indication- and jurisdiction-specific; clinical results are not global marketing permission.&lt;/p&gt;
&lt;h3 id="3-large-clinical-need-is-not-a-revenue-forecast"&gt;&lt;a href="#3-large-clinical-need-is-not-a-revenue-forecast" class="header-anchor"&gt;&lt;/a&gt;3. Large clinical need is not a revenue forecast
&lt;/h3&gt;&lt;p&gt;WHO&amp;#x27;s October 2026 fact sheet estimates that 940 million adults lived with obesity in 2024, about 16% of adults worldwide. &lt;a class="evidence-cite" href="#source-E04" aria-label="Source E04"&gt;[E04]&lt;/a&gt; This establishes the scale of public-health need, not an immediately addressable pharmaceutical market. Diagnosis, authorised indications, contraindications, affordability, reimbursement, clinical capacity and persistence all affect actual treatment numbers.&lt;/p&gt;
&lt;p&gt;The central argument of this report is that the industry is moving beyond increasing supply toward qualifying it, sustaining its use and securing payment. Peptide suppliers depend on product mix, ingredient requirements per treated patient, outsourcing decisions, prices and yields. Branded manufacturers also depend on clinical evidence and market access. Strong end-market demand and factory-level margin pressure can coexist.&lt;/p&gt;
&lt;h2 id="part-2-industry-value-chain"&gt;&lt;a href="#part-2-industry-value-chain" class="header-anchor"&gt;&lt;/a&gt;Part 2: Industry Value Chain
&lt;/h2&gt;&lt;h3 id="1-upstream-inputs-and-the-evidence-that-travels-with-them"&gt;&lt;a href="#1-upstream-inputs-and-the-evidence-that-travels-with-them" class="header-anchor"&gt;&lt;/a&gt;1. Upstream: inputs and the evidence that travels with them
&lt;/h3&gt;&lt;p&gt;Chemical routes begin with protected amino acids, solid supports, coupling and deprotection reagents, solvents and related inputs. Suppliers provide batch consistency, impurity control, reliable deliveries and traceable documentation as well as materials. Changing an input can affect a commercial manufacturing process; a cheaper substitute is not necessarily interchangeable. Verified representative activities appear in the map and appendix. Category connections are not confirmed supply contracts. &lt;a class="evidence-cite" href="#source-C01" aria-label="Source C01"&gt;[C01]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-C02" aria-label="Source C02"&gt;[C02]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Equipment spans synthesis vessels, preparative chromatography, filtration, concentration, drying, analytical instruments and consumables. Equipment sales, recurring consumables and services have different cash-flow patterns. A plant expansion can produce a large equipment order, while ongoing operation drives consumable demand. Reactor volume, resin loading and nominal capacity cannot be converted directly into finished-drug output.&lt;/p&gt;
&lt;p&gt;Biological routes add cell systems, media, fermentation and biological separation. EMA&amp;#x27;s Ozempic product information identifies recombinant production in Saccharomyces cerevisiae cells. &lt;a class="evidence-cite" href="#source-E06" aria-label="Source E06"&gt;[E06]&lt;/a&gt; Peptides therefore cannot be reduced to a single solid-phase-synthesis market. The molecule, intellectual property and manufacturing route determine which suppliers and assets matter.&lt;/p&gt;
&lt;h3 id="2-midstream-turning-a-sequence-into-releasable-api"&gt;&lt;a href="#2-midstream-turning-a-sequence-into-releasable-api" class="header-anchor"&gt;&lt;/a&gt;2. Midstream: turning a sequence into releasable API
&lt;/h3&gt;&lt;p&gt;Solid-phase synthesis assembles amino-acid units on a support before downstream processing. Industrial production also requires modification, purification, impurity characterisation, validation and release. Incomplete reactions and side products influence the difficulty of purification. Commercial value lies in reproducibly delivering material to the same specification, not simply making a sequence once. Products may use solid-phase, liquid-phase, fragment-based, recombinant or hybrid routes rather than one universal GLP-1 process. &lt;a class="evidence-cite" href="#source-C03" aria-label="Source C03"&gt;[C03]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-E06" aria-label="Source E06"&gt;[E06]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Bachem, PolyPeptide and CordenPharma illustrate specialist peptide manufacturing; relevant Chinese capability includes WuXi AppTec&amp;#x27;s WuXi TIDES platform. Company and segment definitions matter: TIDES includes oligonucleotides as well as peptides, so its revenue is not GLP-1 revenue. Demonstrated process capability does not establish a supply relationship with a named marketed brand. &lt;a class="evidence-cite" href="#source-C04" aria-label="Source C04"&gt;[C04]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-C05" aria-label="Source C05"&gt;[C05]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-C06" aria-label="Source C06"&gt;[C06]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-C12" aria-label="Source C12"&gt;[C12]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;CDMO revenue can come from development, clinical batches, transfer, commercial production and capacity arrangements. Numerous development projects need not mean substantial near-term tonnage; a large commercial product can create concentration risk. Supplier transfers require technical and quality work, supporting customer retention. Customer insourcing, project failures and changing forecasts can nevertheless reduce utilisation.&lt;/p&gt;
&lt;p&gt;Chinese participation extends beyond one platform. Asymchem discloses peptide programmes at development, validation and commercial stages and fragment-based processes; Sinopep-Allsino offers peptide API, CMC and formulation services. Project counts, mixed-segment revenue and actual GLP-1 output are not interchangeable. CordenPharma’s European and US investment plans demonstrate international expansion, but planned 2028 commercial starts cannot be counted as operating 2026 supply. &lt;a class="evidence-cite" href="#source-C09" aria-label="Source C09"&gt;[C09]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-C11" aria-label="Source C11"&gt;[C11]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-C12" aria-label="Source C12"&gt;[C12]&lt;/a&gt;&lt;/p&gt;
&lt;h3 id="3-the-manufacturing-interface-formulation-filling-and-devices"&gt;&lt;a href="#3-the-manufacturing-interface-formulation-filling-and-devices" class="header-anchor"&gt;&lt;/a&gt;3. The manufacturing interface: formulation, filling and devices
&lt;/h3&gt;&lt;p&gt;After API manufacture, injections require formulation stability, container closure, aseptic processing, filling inspection and device reliability. Pens, prefilled syringes, cartridges and vials differ in dose accuracy, user steps, materials, supplier qualification and production-line compatibility. A device supplier&amp;#x27;s platform establishes a capability, not a procurement relationship with a particular brand. &lt;a class="evidence-cite" href="#source-C07" aria-label="Source C07"&gt;[C07]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Oral peptides reduce dependence on injection devices while shifting challenges toward stability, absorption and administration conditions. The 2025 Wegovy tablet label specifies a 25 mg daily maintenance dose and fasting requirements; in 2026 the FDA approved a higher 7.2 mg weekly injection. &lt;a class="evidence-cite" href="#source-E07" aria-label="Source E07"&gt;[E07]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-E08" aria-label="Source E08"&gt;[E08]&lt;/a&gt; These figures illustrate manufacturing demand, not prescribing advice or a clinical ranking.&lt;/p&gt;
&lt;p&gt;The supply-chain implication is that similar patient numbers can require very different quantities of API and packaging. Prescription growth cannot simply be applied to peptide tonnage. A credible demand model needs formulation mix, persistence, ramp-up yields, inventory and the customer&amp;#x27;s outsourcing share.&lt;/p&gt;
&lt;h3 id="4-downstream-who-determines-access"&gt;&lt;a href="#4-downstream-who-determines-access" class="header-anchor"&gt;&lt;/a&gt;4. Downstream: who determines access
&lt;/h3&gt;&lt;p&gt;Branded manufacturers integrate clinical development, registration, intellectual property, production networks and commercial access. Clinicians determine diagnosis and prescribing; payers and intermediaries influence coverage and patient cost; wholesalers, pharmacies and authorised online services deliver products. Their relative importance differs across health systems.&lt;/p&gt;
&lt;p&gt;A branded medicine&amp;#x27;s selling price is not the API supplier&amp;#x27;s available revenue pool. It also supports research, unsuccessful programmes, evidence generation, compliance, commercialisation and manufacturing coordination. List prices, cash prices and manufacturer net realisations must not be mixed. WHO&amp;#x27;s 2025 guidance highlighted cost, health-system readiness and equitable access among the reasons for conditional recommendations. &lt;a class="evidence-cite" href="#source-E05" aria-label="Source E05"&gt;[E05]&lt;/a&gt; Payment and care delivery constrain effective demand alongside chemistry.&lt;/p&gt;
&lt;figure id="industry-map-glp1-peptide-value-chain" class="article-visual" data-visual="map" data-vendor="/vendor/article-visuals/markmap.js" aria-labelledby="industry-map-glp1-peptide-value-chain-0-title"&gt;
 &lt;header class="visual-header"&gt;
 &lt;p class="visual-eyebrow"&gt;INDUSTRY MAP&lt;/p&gt;
 &lt;h3 id="industry-map-glp1-peptide-value-chain-0-title"&gt;Therapeutic peptides and the GLP-1 value chain&lt;/h3&gt;
 &lt;p&gt;Explore inputs, manufacturing and access, including representative companies and technologies.&lt;/p&gt;
 &lt;/header&gt;
 &lt;div class="visual-toolbar" hidden aria-label="Mind map controls"&gt;
 &lt;button type="button" data-action="fit"&gt;Fit to view&lt;/button&gt;
 &lt;button type="button" data-action="expand"&gt;Expand all&lt;/button&gt;
 &lt;button type="button" data-action="collapse"&gt;Collapse&lt;/button&gt;
 &lt;button type="button" data-action="fullscreen"&gt;Full screen&lt;/button&gt;
 &lt;/div&gt;
 &lt;div class="visual-stage" hidden aria-label="Therapeutic peptides and the GLP-1 value chain; a text outline is available below"&gt;&lt;/div&gt;
 &lt;p class="visual-status" role="status" aria-live="polite"&gt;&lt;/p&gt;
 &lt;details class="visual-fallback" open&gt;
 &lt;summary&gt;Read the full text outline&lt;/summary&gt;
 &lt;ul class="visual-outline"&gt;&lt;li&gt;&lt;span&gt;Therapeutic peptides and GLP-1 medicines&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Upstream / Inputs&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Building blocks &amp;amp; reagents&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Merck / Novabiochem [C01]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Solid supports &amp;amp; resins&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Sunresin [C02]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Purification technology&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;YMC / Bachem [C03]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Recombinant route inputs&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Yeast cell systems [E06]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Midstream / Manufacturing&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Specialist peptide APIs&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Bachem [C04]&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;PolyPeptide [C05]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Diversified CDMO platforms&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;WuXi TIDES [C06]&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Asymchem [C09]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;API-to-formulation capability&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Sinopep [C11]&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;CordenPharma [C12]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Fill-finish &amp;amp; device integration&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Novo sites [E01][E02]&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;SHL / Thermo Fisher [C07]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Downstream / Access&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Branded peptide medicines&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Novo Nordisk [M01]&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Lilly [M02]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Clinical &amp;amp; prescribing services&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Clinicians; care providers&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Payment &amp;amp; delivery&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Payers; wholesalers; pharmacies&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Adjacent non-peptide competition&lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;Foundayo / orforglipron [M04]&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;
 &lt;/details&gt;
 &lt;figcaption class="visual-caption"&gt;
 &lt;p&gt;Category connections, not verified supplier contracts. Examples are non-exhaustive, non-exclusive and unranked. The non-peptide branch is a competitive substitute, not peptide manufacturing demand. Source IDs resolve in the evidence appendix.&lt;/p&gt;
 &lt;p&gt;Sources: &lt;a href="https://thedexs.com/post/glp1-peptides/#appendix-evidence-and-methods"&gt;Evidence and sources&lt;/a&gt;. Reviewed 2026-10-21.&lt;/p&gt;
 &lt;/figcaption&gt;
 &lt;script class="visual-data" type="application/json"&gt;{"description":"Explore inputs, manufacturing and access, including representative companies and technologies.","note":"Category connections, not verified supplier contracts. Examples are non-exhaustive, non-exclusive and unranked. The non-peptide branch is a competitive substitute, not peptide manufacturing demand. Source IDs resolve in the evidence appendix.","reviewed":"2026-10-21","root":{"children":[{"children":[{"children":[{"name":"Merck / Novabiochem [C01]"}],"name":"Building blocks \u0026 reagents"},{"children":[{"name":"Sunresin [C02]"}],"name":"Solid supports \u0026 resins"},{"children":[{"name":"YMC / Bachem [C03]"}],"name":"Purification technology"},{"children":[{"name":"Yeast cell systems [E06]"}],"name":"Recombinant route inputs"}],"name":"Upstream / Inputs"},{"children":[{"children":[{"name":"Bachem [C04]"},{"name":"PolyPeptide [C05]"}],"name":"Specialist peptide APIs"},{"children":[{"name":"WuXi TIDES [C06]"},{"name":"Asymchem [C09]"}],"name":"Diversified CDMO platforms"},{"children":[{"name":"Sinopep [C11]"},{"name":"CordenPharma [C12]"}],"name":"API-to-formulation capability"},{"children":[{"name":"Novo sites [E01][E02]"},{"name":"SHL / Thermo Fisher [C07]"}],"name":"Fill-finish \u0026 device integration"}],"name":"Midstream / Manufacturing"},{"children":[{"children":[{"name":"Novo Nordisk [M01]"},{"name":"Lilly [M02]"}],"name":"Branded peptide medicines"},{"children":[{"name":"Clinicians; care providers"}],"name":"Clinical \u0026 prescribing services"},{"children":[{"name":"Payers; wholesalers; pharmacies"}],"name":"Payment \u0026 delivery"},{"children":[{"name":"Foundayo / orforglipron [M04]"}],"name":"Adjacent non-peptide competition"}],"name":"Downstream / Access"}],"name":"Therapeutic peptides and GLP-1 medicines"},"sources":[{"title":"Evidence and sources","url":"/post/glp1-peptides/#appendix-evidence-and-methods"}],"title":"Therapeutic peptides and the GLP-1 value chain"}&lt;/script&gt;
&lt;/figure&gt;

&lt;h2 id="part-3-market-landscape"&gt;&lt;a href="#part-3-market-landscape" class="header-anchor"&gt;&lt;/a&gt;Part 3: Market Landscape
&lt;/h2&gt;&lt;h3 id="1-comparable-shares-first-financial-scale-second"&gt;&lt;a href="#1-comparable-shares-first-financial-scale-second" class="header-anchor"&gt;&lt;/a&gt;1. Comparable shares first, financial scale second
&lt;/h3&gt;&lt;p&gt;Novo Nordisk&amp;#x27;s FY 2025 report cites IQVIA data showing a 45.8% global GLP-1 diabetes value share for the moving annual total ending November 2025, versus 55.1% a year earlier, a decline of 9.3 percentage points. &lt;a class="evidence-cite" href="#source-M01" aria-label="Source M01"&gt;[M01]&lt;/a&gt; The donut therefore contains only Novo Nordisk, 45.8%, and other manufacturers combined, 54.2%. The residual is calculated as 100% minus 45.8%; it must not be labelled entirely as Lilly.&lt;/p&gt;
&lt;p&gt;The denominator is the source-defined GLP-1 diabetes value market. International tirzepatide is classified as diabetes even where it also has an obesity indication, and some regional coverage is incomplete. This is not the whole obesity-drug, peptide API or CDMO market, nor audited manufacturer net sales. The historical period remains explicit rather than being presented as a live October 2026 share. &lt;a class="evidence-cite" href="#source-M01" aria-label="Source M01"&gt;[M01]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Company revenue gives a separate scale indicator. Novo reported FY 2025 GLP-1 diabetes sales of DKK 152.202 billion and obesity-care sales of DKK 82.347 billion. Lilly reported worldwide Mounjaro and Zepbound revenue of US$22.965 billion and US$13.542 billion, respectively, totalling US$36.507 billion. &lt;a class="evidence-cite" href="#source-M01" aria-label="Source M01"&gt;[M01]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-M02" aria-label="Source M02"&gt;[M02]&lt;/a&gt; Currencies are not combined, and brand-indication relationships differ by country. These figures cannot establish whole-value-chain shares.&lt;/p&gt;
&lt;figure id="market-share-glp1-diabetes-value-mat-nov-2025" class="article-visual" data-visual="share" data-vendor="/vendor/article-visuals/echarts.js" aria-labelledby="market-share-glp1-diabetes-value-mat-nov-2025-1-title"&gt;
 &lt;header class="visual-header"&gt;
 &lt;p class="visual-eyebrow"&gt;MARKET SHARE · MAT to November 2025&lt;/p&gt;
 &lt;h3 id="market-share-glp1-diabetes-value-mat-nov-2025-1-title"&gt;Reported global GLP-1 diabetes value share&lt;/h3&gt;
 &lt;p&gt;Source-defined GLP-1 diabetes market, not all obesity medicines, peptide APIs or CDMOs. IQVIA moving annual total to November 2025, as reported by Novo Nordisk.&lt;/p&gt;
 &lt;p class="visual-meta"&gt;Worldwide (source coverage) · Share of market value (%)&lt;/p&gt;
 &lt;/header&gt;
 &lt;div class="visual-toolbar" hidden aria-label="Chart controls"&gt;
 &lt;button type="button" data-action="fullscreen"&gt;Full screen&lt;/button&gt;
 &lt;/div&gt;
 &lt;div class="visual-stage" hidden aria-label="Reported global GLP-1 diabetes value share; exact percentages are available in the table below"&gt;&lt;/div&gt;
 &lt;p class="visual-status" role="status" aria-live="polite"&gt;&lt;/p&gt;
 &lt;details class="visual-fallback" open&gt;
 &lt;summary&gt;View the data table&lt;/summary&gt;
 &lt;div class="table-wrapper"&gt;
 &lt;table class="visual-table"&gt;
 &lt;caption&gt;Reported global GLP-1 diabetes value share · MAT to November 2025 · Share of market value (%)&lt;/caption&gt;
 &lt;thead&gt;&lt;tr&gt;&lt;th scope="col"&gt;Manufacturer&lt;/th&gt;&lt;th scope="col"&gt;Share&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;
 &lt;tbody&gt;&lt;tr&gt;&lt;th scope="row"&gt;Novo Nordisk&lt;/th&gt;&lt;td&gt;45.8%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Other manufacturers combined&lt;/th&gt;&lt;td&gt;54.2%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
 &lt;/table&gt;
 &lt;/div&gt;
 &lt;a class="visual-download" href="https://thedexs.com/data/charts/glp1-diabetes-value-mat-nov-2025.csv" download&gt;Download data (CSV)&lt;/a&gt;
 &lt;/details&gt;
 &lt;figcaption class="visual-caption"&gt;
 &lt;p&gt;Other = 100% − 45.8% = 54.2%, not Lilly alone. International tirzepatide is classified as diabetes in the source, including where an obesity indication exists; regional coverage is incomplete. These are historical market-value estimates, not audited manufacturer net sales.&lt;/p&gt;
 &lt;p&gt;Source: &lt;a href="https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm"&gt;Novo Nordisk, citing IQVIA — [M01] Financial report for the year 2025&lt;/a&gt; (2026-02-03). Reviewed 2026-10-21.&lt;/p&gt;
 &lt;/figcaption&gt;
 &lt;script class="visual-data" type="application/json"&gt;{"center_label":"MAT NOV 2025","dimension":"Manufacturer","geography":"Worldwide (source coverage)","metric":"Share of market value (%)","note":"Other = 100% − 45.8% = 54.2%, not Lilly alone. International tirzepatide is classified as diabetes in the source, including where an obesity indication exists; regional coverage is incomplete. These are historical market-value estimates, not audited manufacturer net sales.","percentDecimals":1,"period":"MAT to November 2025","reviewed":"2026-10-21","scope":"Source-defined GLP-1 diabetes market, not all obesity medicines, peptide APIs or CDMOs. IQVIA moving annual total to November 2025, as reported by Novo Nordisk.","series":[{"name":"Novo Nordisk","value":45.8},{"derived":true,"name":"Other manufacturers combined","value":54.2}],"source":{"locator":"Financial report p.7, GLP-1 diabetes table and footnotes; annual report therapeutic sales","published":"2026-02-03","publisher":"Novo Nordisk, citing IQVIA","title":"[M01] Financial report for the year 2025","url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm"},"title":"Reported global GLP-1 diabetes value share","unit":"%"}&lt;/script&gt;
&lt;/figure&gt;

&lt;h3 id="2-reading-2026-growth-without-mixing-accounting-and-demand"&gt;&lt;a href="#2-reading-2026-growth-without-mixing-accounting-and-demand" class="header-anchor"&gt;&lt;/a&gt;2. Reading 2026 growth without mixing accounting and demand
&lt;/h3&gt;&lt;p&gt;Lilly&amp;#x27;s first-half 2026 Mounjaro and Zepbound revenue was US$18.605 billion and US$9.088 billion, totalling US$27.693 billion. Foundayo generated US$98 million. &lt;a class="evidence-cite" href="#source-M06" aria-label="Source M06"&gt;[M06]&lt;/a&gt; Revenue demonstrates that commercialisation has begun; a small launch-period base does not justify extrapolating long-term share.&lt;/p&gt;
&lt;p&gt;Novo&amp;#x27;s first-half 2026 statements include a DKK 26.760 billion reversal of a US 340B provision. Total reported sales were DKK 175.311 billion, versus adjusted sales of DKK 148.551 billion. &lt;a class="evidence-cite" href="#source-M05" aria-label="Source M05"&gt;[M05]&lt;/a&gt; Reported revenue changes cannot all be interpreted as additional drug volumes, much less API demand. Accounting adjustments, currencies, net prices, mix and periods must be reconciled first.&lt;/p&gt;
&lt;p&gt;For suppliers, the useful questions are how price and volume separate, how much manufacturing is captive, which molecular formats create demand, and whether channel growth reflects new patients, switching or inventory. These variables connect medicine sales to actual manufacturing orders.&lt;/p&gt;
&lt;figure id="research-table-glp1-revenue-comparison-2" class="article-visual research-table research-table--wide" aria-labelledby="research-table-glp1-revenue-comparison-2-title"&gt;
 &lt;header class="visual-header"&gt;
 &lt;p class="visual-eyebrow"&gt;RESEARCH DATA&lt;/p&gt;
 &lt;h3 id="research-table-glp1-revenue-comparison-2-title"&gt;Company-disclosed sales: keep periods and currencies separate&lt;/h3&gt;
 &lt;p&gt;Selected disclosures reproduced from the report, not a market-share calculation.&lt;/p&gt;
 &lt;/header&gt;
 &lt;p id="research-table-glp1-revenue-comparison-2-scroll-hint" class="research-table-scroll-hint"&gt;Scroll horizontally to read all columns.&lt;/p&gt;
 &lt;div class="research-table-scroll" role="region" tabindex="0" aria-labelledby="research-table-glp1-revenue-comparison-2-title" aria-describedby="research-table-glp1-revenue-comparison-2-scroll-hint"&gt;
 &lt;table class="research-data-table"&gt;
 &lt;caption class="research-table-caption-hidden"&gt;Company-disclosed sales: keep periods and currencies separate&lt;/caption&gt;
 &lt;thead&gt;&lt;tr&gt;&lt;th scope="col"&gt;Company / measure&lt;/th&gt;&lt;th scope="col"&gt;Period&lt;/th&gt;&lt;th scope="col"&gt;Currency&lt;/th&gt;&lt;th scope="col" class="research-table-number"&gt;Amount (billion)&lt;/th&gt;&lt;th scope="col"&gt;Interpretation / source&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;
 &lt;tbody&gt;&lt;tr&gt;&lt;th scope="row"&gt;Novo Nordisk: GLP-1 diabetes sales&lt;/th&gt;&lt;td&gt;FY2025&lt;/td&gt;&lt;td&gt;DKK&lt;/td&gt;&lt;td class="research-table-number"&gt;152.202&lt;/td&gt;&lt;td&gt;Diabetes business measure &lt;a class="evidence-cite" href="#source-M01" aria-label="Source M01"&gt;[M01]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Novo Nordisk: obesity-care sales&lt;/th&gt;&lt;td&gt;FY2025&lt;/td&gt;&lt;td&gt;DKK&lt;/td&gt;&lt;td class="research-table-number"&gt;82.347&lt;/td&gt;&lt;td&gt;Not interchangeable with diabetes sales &lt;a class="evidence-cite" href="#source-M01" aria-label="Source M01"&gt;[M01]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Lilly: Mounjaro&lt;/th&gt;&lt;td&gt;FY2025&lt;/td&gt;&lt;td&gt;USD&lt;/td&gt;&lt;td class="research-table-number"&gt;22.965&lt;/td&gt;&lt;td&gt;Worldwide brand revenue &lt;a class="evidence-cite" href="#source-M02" aria-label="Source M02"&gt;[M02]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Lilly: Zepbound&lt;/th&gt;&lt;td&gt;FY2025&lt;/td&gt;&lt;td&gt;USD&lt;/td&gt;&lt;td class="research-table-number"&gt;13.542&lt;/td&gt;&lt;td&gt;Worldwide brand revenue &lt;a class="evidence-cite" href="#source-M02" aria-label="Source M02"&gt;[M02]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Lilly: Mounjaro&lt;/th&gt;&lt;td&gt;H1 2026&lt;/td&gt;&lt;td&gt;USD&lt;/td&gt;&lt;td class="research-table-number"&gt;18.605&lt;/td&gt;&lt;td&gt;Half-year, not annual &lt;a class="evidence-cite" href="#source-M06" aria-label="Source M06"&gt;[M06]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Lilly: Zepbound&lt;/th&gt;&lt;td&gt;H1 2026&lt;/td&gt;&lt;td&gt;USD&lt;/td&gt;&lt;td class="research-table-number"&gt;9.088&lt;/td&gt;&lt;td&gt;Half-year, not annual &lt;a class="evidence-cite" href="#source-M06" aria-label="Source M06"&gt;[M06]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Lilly: Foundayo&lt;/th&gt;&lt;td&gt;H1 2026&lt;/td&gt;&lt;td&gt;USD&lt;/td&gt;&lt;td class="research-table-number"&gt;0.098&lt;/td&gt;&lt;td&gt;Early launch revenue; non-peptide drug &lt;a class="evidence-cite" href="#source-M06" aria-label="Source M06"&gt;[M06]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Novo Nordisk: total reported sales&lt;/th&gt;&lt;td&gt;H1 2026&lt;/td&gt;&lt;td&gt;DKK&lt;/td&gt;&lt;td class="research-table-number"&gt;175.311&lt;/td&gt;&lt;td&gt;Includes 340B provision reversal &lt;a class="evidence-cite" href="#source-M05" aria-label="Source M05"&gt;[M05]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Novo Nordisk: 340B provision reversal&lt;/th&gt;&lt;td&gt;H1 2026&lt;/td&gt;&lt;td&gt;DKK&lt;/td&gt;&lt;td class="research-table-number"&gt;26.760&lt;/td&gt;&lt;td&gt;Accounting adjustment, not additional volume &lt;a class="evidence-cite" href="#source-M05" aria-label="Source M05"&gt;[M05]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th scope="row"&gt;Novo Nordisk: adjusted sales&lt;/th&gt;&lt;td&gt;H1 2026&lt;/td&gt;&lt;td&gt;DKK&lt;/td&gt;&lt;td class="research-table-number"&gt;148.551&lt;/td&gt;&lt;td&gt;175.311 − 26.760 &lt;a class="evidence-cite" href="#source-M05" aria-label="Source M05"&gt;[M05]&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
 &lt;/table&gt;
 &lt;/div&gt;
 &lt;figcaption class="visual-caption"&gt;&lt;p&gt;Do not sum currencies, overlap brand sales with company totals, or add half-year and annual observations. Brand revenue cannot establish API or CDMO demand or whole-value-chain shares. Values come from &lt;a class="evidence-cite" href="#source-M01" aria-label="Source M01"&gt;[M01]&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-M02" aria-label="Source M02"&gt;[M02]&lt;/a&gt;, &lt;a class="evidence-cite" href="#source-M05" aria-label="Source M05"&gt;[M05]&lt;/a&gt; and &lt;a class="evidence-cite" href="#source-M06" aria-label="Source M06"&gt;[M06]&lt;/a&gt;.&lt;/p&gt;&lt;/figcaption&gt;
&lt;/figure&gt;
&lt;h3 id="3-three-competitive-layers-not-one-company-ranking"&gt;&lt;a href="#3-three-competitive-layers-not-one-company-ranking" class="header-anchor"&gt;&lt;/a&gt;3. Three competitive layers, not one company ranking
&lt;/h3&gt;&lt;p&gt;The first layer comprises originators with clinical evidence, authorisations, brands and access. Novo and Lilly also manufacture internally. The opportunity for outside suppliers is the demand available after captive production and other constraints, not all downstream medicine revenue.&lt;/p&gt;
&lt;p&gt;The second layer comprises specialist manufacturing and process platforms. Quality systems, scale-up, delivery records and transfer capability win projects. Bachem&amp;#x27;s commercial GMP batches from a new building and PolyPeptide&amp;#x27;s utilisation ramp illustrate a shift from announcing assets to operating them. Manufacturer capacity statements are not independently measured industry shares. &lt;a class="evidence-cite" href="#source-C04" aria-label="Source C04"&gt;[C04]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-C05" aria-label="Source C05"&gt;[C05]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;The third layer comprises new molecules, formulations, generics and regional competitors. The FDA&amp;#x27;s 2024 approval of the first generic referencing Victoza demonstrates an established-product pathway, not identical development difficulty or market rights across all peptides. &lt;a class="evidence-cite" href="#source-E09" aria-label="Source E09"&gt;[E09]&lt;/a&gt; Novo still described CagriSema as investigational on 20 October 2026; retatrutide also cannot be assigned an approved-product sales share. &lt;a class="evidence-cite" href="#source-M07" aria-label="Source M07"&gt;[M07]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-E10" aria-label="Source E10"&gt;[E10]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Chinese process-development and manufacturing capability is distinct from competition in China&amp;#x27;s finished-drug market. Growth at WuXi TIDES supports the former, not automatic leadership in the latter. &lt;a class="evidence-cite" href="#source-C06" aria-label="Source C06"&gt;[C06]&lt;/a&gt; Nor does expiry of a compound patent eliminate all process, formulation, use or regulatory barriers. &lt;a class="evidence-cite" href="#source-C08" aria-label="Source C08"&gt;[C08]&lt;/a&gt;&lt;/p&gt;
&lt;h3 id="4-geography-changes-the-business-model"&gt;&lt;a href="#4-geography-changes-the-business-model" class="header-anchor"&gt;&lt;/a&gt;4. Geography changes the business model
&lt;/h3&gt;&lt;p&gt;The United States illustrates interactions among commercial scale, net prices, insurance and direct-to-patient channels, but its shortage and compounding rules are not global rules. In Europe, EU authorisation must be separated from country-level access, reimbursement and launch. China combines an innovative-drug market, manufacturing services and domestic competition.&lt;/p&gt;
&lt;p&gt;A global forecast therefore needs a region-by-product matrix. Lower prices can expand coverage while reducing net revenue per unit; an authorisation elsewhere may precede meaningful sales. For Chinese suppliers, international capability requires verifiable quality, regulatory support, customer relationships and local compliance, not simply export orders. No single price, patent date or regional prescription trend represents the world.&lt;/p&gt;
&lt;h2 id="part-4-industry-problems"&gt;&lt;a href="#part-4-industry-problems" class="header-anchor"&gt;&lt;/a&gt;Part 4: Industry Problems
&lt;/h2&gt;&lt;h3 id="1-after-expansion-utilisation-and-unit-cost-matter"&gt;&lt;a href="#1-after-expansion-utilisation-and-unit-cost-matter" class="header-anchor"&gt;&lt;/a&gt;1. After expansion, utilisation and unit cost matter
&lt;/h3&gt;&lt;p&gt;Bachem reported commercial GMP batches from Building K in the first half of 2026, while ramp-up costs weighed on profitability: its EBITDA margin fell to 25.4% from 29.1%. PolyPeptide’s half-year 2026 report says its Belgian large-scale solid-phase-synthesis plant operated at target utilisation, while other sites still had assets in commissioning or ramp-up. &lt;a class="evidence-cite" href="#source-C04" aria-label="Source C04"&gt;[C04]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-C05" aria-label="Source C05"&gt;[C05]&lt;/a&gt; These are company examples, not industry averages, but they contradict the assumption that completed capacity immediately releases profit.&lt;/p&gt;
&lt;p&gt;Training, validation, commissioning and fixed costs precede the gradual increase in saleable batches. Synthesis, purification, analysis and release can become mismatched. Staged expansion, process improvement, appropriate long-term contracts and customer diversification can help; commitments can also lock in unattractive prices or the wrong mix.&lt;/p&gt;
&lt;p&gt;Diligence should examine released batches, qualified output, utilisation, failures and reprocessing, delivery and cash collection rather than vessel litres, floor space or announced spending alone. Where comparable data are absent, a blank is more informative than a manufactured global share.&lt;/p&gt;
&lt;h3 id="2-quality-environmental-burden-and-resilience-remain-responsibilities"&gt;&lt;a href="#2-quality-environmental-burden-and-resilience-remain-responsibilities" class="header-anchor"&gt;&lt;/a&gt;2. Quality, environmental burden and resilience remain responsibilities
&lt;/h3&gt;&lt;p&gt;Scale-up means more than enlarging a vessel. Impurities can resemble the target molecule, while purification consumes time, solvents and equipment capacity. Larger batches increase the consequences of a deviation. Lower-solvent and improved routes can benefit both cost and environmental performance, provided quality remains demonstrated. &lt;a class="evidence-cite" href="#source-C03" aria-label="Source C03"&gt;[C03]&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Compliance and process capability create opportunity and risk for Chinese and other international suppliers. FDA&amp;#x27;s GLP-1 API import alert focuses on quality and manufacturing compliance rather than prohibiting all foreign API. &lt;a class="evidence-cite" href="#source-E10" aria-label="Source E10"&gt;[E10]&lt;/a&gt; Assessment should be site-, product- and status-specific, not based on nationality alone.&lt;/p&gt;
&lt;p&gt;Second sources, critical-input inventories and alternative routes can improve resilience but require qualification and cost. Resilience does not mean duplicating every asset. Scarce materials, specialist equipment, concentrated customers and single-site dependence need different buffers.&lt;/p&gt;
&lt;p&gt;Hybio describes work at its Wuhan site to segregate and recover waste from synthesis, cleavage and purification. This provides a concrete example of disposal infrastructure becoming a condition for expanding crude-peptide output. The announcement is a project account, not a quantified realised saving. &lt;a class="evidence-cite" href="#source-C10" aria-label="Source C10"&gt;[C10]&lt;/a&gt;&lt;/p&gt;
&lt;h3 id="3-access-and-persistence-constrain-the-demand-model"&gt;&lt;a href="#3-access-and-persistence-constrain-the-demand-model" class="header-anchor"&gt;&lt;/a&gt;3. Access and persistence constrain the demand model
&lt;/h3&gt;&lt;p&gt;The end market is not simply the population with obesity multiplied by one year&amp;#x27;s list price. Clinical need does not ensure diagnosis, reimbursement or continuous prescriptions, and treatment initiation does not ensure full-year persistence. WHO included affordability, health-system capacity and long-term evidence among its considerations. &lt;a class="evidence-cite" href="#source-E05" aria-label="Source E05"&gt;[E05]&lt;/a&gt; Access is part of demand conversion, not a footnote added after a sales forecast.&lt;/p&gt;
&lt;p&gt;Clinical competition also cannot be ranked by weight-loss percentages from unrelated trials. Populations, follow-up, diabetes status, estimands and treatment-discontinuation handling differ. Industrial analysis should consider tolerability, follow-up, persistence and disease outcomes rather than treating promotional summaries or simple cross-trial comparisons as head-to-head evidence.&lt;/p&gt;
&lt;p&gt;For suppliers this creates ordering variability: starts generate initial demand, maintenance drives continued consumption, and payment and formulation changes alter mix. Scenarios should vary these drivers separately rather than apply one growth rate to the entire industry.&lt;/p&gt;
&lt;h3 id="4-generics-compounding-and-research-products-are-distinct"&gt;&lt;a href="#4-generics-compounding-and-research-products-are-distinct" class="header-anchor"&gt;&lt;/a&gt;4. Generics, compounding and research products are distinct
&lt;/h3&gt;&lt;p&gt;Approved generics follow an applicable approval pathway; compounded medicines do not undergo FDA premarket review for safety, effectiveness and quality. FDA&amp;#x27;s public warnings address dosing errors, shipping conditions and misrepresented sources, and identify retatrutide and cagrilintide as not being components of FDA-approved medicines. &lt;a class="evidence-cite" href="#source-E09" aria-label="Source E09"&gt;[E09]&lt;/a&gt;&lt;a class="evidence-cite" href="#source-E10" aria-label="Source E10"&gt;[E10]&lt;/a&gt; Online “research-use” sales should not be counted as ordinary compliant finished-drug demand or treated as equivalent approved alternatives.&lt;/p&gt;
&lt;p&gt;Changes following shortage resolution also distinguish demand based on temporary regulatory conditions from demand supported by enduring registrations and clinical evidence. &lt;a class="evidence-cite" href="#source-E03" aria-label="Source E03"&gt;[E03]&lt;/a&gt; This does not mean that every compounded preparation is unlawful: legality depends on specific conditions, actors and products.&lt;/p&gt;
&lt;p&gt;Intellectual property is similarly layered. Novo&amp;#x27;s disclosed compound-patent dates do not extinguish every other right, and Chinese litigation involves disputed extended exclusivity; the disclosed allegations are party claims, not final judicial findings. &lt;a class="evidence-cite" href="#source-C08" aria-label="Source C08"&gt;[C08]&lt;/a&gt; Expiry is not a guarantee that any competitor can immediately launch without country-, patent- and regulatory-level checks.&lt;/p&gt;
&lt;h3 id="5-conclusion-prove-the-value-of-capacity"&gt;&lt;a href="#5-conclusion-prove-the-value-of-capacity" class="header-anchor"&gt;&lt;/a&gt;5. Conclusion: prove the value of capacity
&lt;/h3&gt;&lt;p&gt;Long-term opportunity comes from large chronic-disease needs and continued innovation in drug formats, but value will not accrue equally to every capacity expansion. Originators compete on evidence and access; process platforms on quality and delivery; input and equipment suppliers on dependable standardised supply; channels on continuous, compliant service.&lt;/p&gt;
&lt;p&gt;Five signals deserve attention: qualified output and utilisation at new plants; the actual mix of injectable peptides, oral peptides and non-peptide medicines; net prices and coverage; jurisdiction-specific registrations and rights; and suppliers&amp;#x27; ability to build durable customer portfolios. These signals must be connected before treating GLP-1 demand as a guarantee of supplier profit.&lt;/p&gt;
&lt;p&gt;&lt;span id="supporting-evidence"&gt;&lt;/span&gt;&lt;/p&gt;
&lt;h2 id="appendix-evidence-and-methods"&gt;&lt;a href="#appendix-evidence-and-methods" class="header-anchor"&gt;&lt;/a&gt;Appendix: Evidence and Methods
&lt;/h2&gt;&lt;p&gt;Methods and calculations: regulatory records, company disclosures and official statistical synthesis. Company results and project progress are issuer disclosures; market shares are issuer-reported third-party estimates. Explanations of bottlenecks, value allocation and demand conversion are author analysis. Donut residual=100−45.8=54.2%; share change=45.8−55.1=−9.3 percentage points. Lilly two-brand FY2025 total=22,965+13,542=US$36,507m; H1 2026 total=18,605+9,088=US$27,693m. Novo H1 reconciliation=175,311−26,760=DKK148,551m. Currencies are not blended; branded sales, API sales and CDMO sales are not added; incompatible supplier metrics are not used to calculate CDMO shares.&lt;/p&gt;
&lt;section class="research-evidence" id="source-E01" aria-labelledby="heading-E01"&gt;&lt;h3 id="heading-E01"&gt;[E01] The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Novo Nordisk&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2024-12-18&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Transaction completed 18 Dec 2024; three manufacturing sites&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Company announcement 98/2024, opening paragraphs&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Confirms completion and the distinction between the two acquirers.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Does not establish site-level GLP-1 output or utilisation.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915081" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E02" aria-labelledby="heading-E02"&gt;&lt;h3 id="heading-E02"&gt;[E02] Catalent Clarifies Novo Nordisk Ownership of Former Bloomington, Indiana Site&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Catalent&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-06-22&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Bloomington, Indiana; ownership since Dec 2024&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Main statement, ownership paragraphs&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Confirms ownership and operation by Novo Nordisk.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Legacy filing names do not establish current ownership.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://catalent.com/news/catalent-clarifies-novo-nordisk-ownership-of-former-bloomington-indiana-site" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E03" aria-labelledby="heading-E03"&gt;&lt;h3 id="heading-E03"&gt;[E03] Resolution of Shortages of Semaglutide Injection Products; FDA policies for compounders&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US FDA&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2025-02-21; policy page subsequently updated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; US national semaglutide-injection shortage determination&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Order pp.1–3; policy page entries dated 21 Feb 2025 and later&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Supports national resolution, possible local disruptions and changed shortage-related conditions.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Historical decision, not every GLP-1 product or worldwide availability; not legal advice.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.fda.gov/media/185526/download" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt; · &lt;a href="https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize" target="_blank" rel="noopener"&gt;Source 2&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E04" aria-labelledby="heading-E04"&gt;&lt;h3 id="heading-E04"&gt;[E04] Obesity and overweight&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; WHO&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-10-07&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Global adults aged 18+; 2024 estimates&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Key facts; Prevalence of overweight and obesity&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; An estimated 940 million adults had obesity in 2024, about 16% of adults.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Prevalence is not a paid pharmaceutical market or prescription forecast.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Official statistical synthesis&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E05" aria-labelledby="heading-E05"&gt;&lt;h3 id="heading-E05"&gt;[E05] WHO issues global guideline on the use of GLP-1 medicines in treating obesity&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; WHO&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2025-12-01&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Global guideline context; adult obesity&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Landmark policy change; Implementation considerations&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Cost, long-term evidence, system readiness and equity inform conditional recommendations.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Guidance is not country-level reimbursement or product approval; not personal prescribing advice.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E06" aria-labelledby="heading-E06"&gt;&lt;h3 id="heading-E06"&gt;[E06] Ozempic: Summary of Product Characteristics&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; European Medicines Agency&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Live product information; read 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Assessed originator semaglutide product&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Annex I, section 2, printed p.3&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Identifies recombinant Saccharomyces cerevisiae manufacture.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Not all suppliers or proof of universally lowest process cost.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E07" aria-labelledby="heading-E07"&gt;&lt;h3 id="heading-E07"&gt;[E07] Wegovy injection and tablets: Prescribing information&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US FDA&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Revised 12/2025&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; US approval-era label; formulations and strengths&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Sections 2.1–2.3, printed pp.4–5; section 11&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Supports 25 mg daily tablet maintenance and administration conditions, used to discuss input demand.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Historical label, not comprehensive current prescribing guidance; dose is not comparative efficacy.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E08" aria-labelledby="heading-E08"&gt;&lt;h3 id="heading-E08"&gt;[E08] FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US FDA&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-03-19&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; US approval; Wegovy HD 7.2 mg injection&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Opening and indication paragraphs; SEC-filed 19 March 2026 announcement, opening paragraph for once-weekly schedule&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Confirms higher-dose injectable approval beyond the 2025 label.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Not prescribing advice or an indirect efficacy ranking.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt; · &lt;a href="https://www.sec.gov/Archives/edgar/data/353278/000117184326001813/f6k_031926.htm" target="_blank" rel="noopener"&gt;Source 2&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E09" aria-labelledby="heading-E09"&gt;&lt;h3 id="heading-E09"&gt;[E09] FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US FDA&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2024-12-23&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; US; generic referencing Victoza&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Opening paragraph and approval recipient&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Confirms first generic approval referencing Victoza.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Does not imply identical generic pathways or immediate access for every GLP-1.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-E10" aria-labelledby="heading-E10"&gt;&lt;h3 id="heading-E10"&gt;[E10] FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US FDA&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Live page; accessed 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; US regulatory and quality warnings&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Unapproved versions; Retatrutide and cagrilintide; Actions at the border; Shipping; Dosing concerns&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Supports distinctions from approved products, investigational ingredients, quality and import risks.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Warnings are not incidence estimates; import alert is not a blanket country ban.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-M01" aria-labelledby="heading-M01"&gt;&lt;h3 id="heading-M01"&gt;[M01] Financial report for 1 January–31 December 2025; Annual Report 2025&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Novo Nordisk&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-02-03&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Global IQVIA value share, MAT November 2025; separate FY 2025 company sales, DKK&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Financial report p.7, GLP-1 diabetes table and footnotes; annual report therapeutic sales&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Share 45.8%, prior 55.1%; diabetes GLP-1 sales DKK 152,202 m, obesity DKK 82,347 m.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Issuer-reported IQVIA; international tirzepatide classified as diabetes, incomplete coverage; share differs from net-sales basis.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary issuer record containing third-party estimates&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt; · &lt;a href="https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html" target="_blank" rel="noopener"&gt;Source 2&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-M02" aria-labelledby="heading-M02"&gt;&lt;h3 id="heading-M02"&gt;[M02] Lilly reports fourth-quarter 2025 financial results and provides 2026 financial guidance&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Eli Lilly&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-02-04&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Worldwide FY 2025 brand revenue, USD millions&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Selected Revenue Highlights&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Mounjaro US$22,965 m and Zepbound US$13,542 m; sum US$36,507 m.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Brands do not map universally to one indication; not all Lilly GLP-1 revenue.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-2025-financial-results-and-provides" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-M03" aria-labelledby="heading-M03"&gt;&lt;h3 id="heading-M03"&gt;[M03] Wegovy tablets original approval package&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US FDA&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2025-12-22 approval&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; US; adult indications specified in letter&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Approval letter, package pp.1 and 4&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Confirms approved oral semaglutide rather than pipeline-only technology.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; US approval is not simultaneous worldwide launch.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000Approv.pdf" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-M04" aria-labelledby="heading-M04"&gt;&lt;h3 id="heading-M04"&gt;[M04] Foundayo approval letter and non-peptide product description&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; US FDA; Eli Lilly&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-04-01&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; US adult weight-management approval; molecular modality&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; FDA letter p.1 for approval and p.12 electronic signature for date; Lilly About Foundayo&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Confirms orforglipron approval and non-peptide small-molecule modality.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; No inference of other authorisations or universal suitability; not peptide API demand.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220934Orig1s000ltr.pdf" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt; · &lt;a href="https://lilly.gcs-web.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill" target="_blank" rel="noopener"&gt;Source 2&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-M05" aria-labelledby="heading-M05"&gt;&lt;h3 id="heading-M05"&gt;[M05] Financial report for 1 January–30 June 2026&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Novo Nordisk&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-08-04&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; H1 2026; DKK millions; interim unaudited/unreviewed&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Pages 3–4,8–10,13; adjusted results and 340 B reversal&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; 340 B reversal DKK 26,760 m; reported sales 175,311 m versus adjusted 148,551 m.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Adjusted metrics are non-IFRS measures; revenue changes are not volume changes.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-M06" aria-labelledby="heading-M06"&gt;&lt;h3 id="heading-M06"&gt;[M06] Lilly reports second-quarter 2026 financial results&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Eli Lilly&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-08-05&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Worldwide H1 2026; USD millions&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Selected Revenue Highlights, six-month column&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Mounjaro US$18,605 m, Zepbound US$9,088 m, Foundayo US$98 m.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Launch sales are not long-term share forecasts; stated sum excludes Trulicity.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-M07" aria-labelledby="heading-M07"&gt;&lt;h3 id="heading-M07"&gt;[M07] Novo’s CagriSema was associated with 25% weight loss on average for women… [title abbreviated; REDEFINE 1 post hoc announcement]&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Novo Nordisk&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-10-20&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Pipeline status at report cutoff&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Opening bullets and investigational description&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Still describes CagriSema as investigational.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Cited only for investigational status, not efficacy estimates. Results and expected decisions are not approval.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=918569" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C01" aria-labelledby="heading-C01"&gt;&lt;h3 id="heading-C01"&gt;[C01] HATU, Novabiochem, product 851013&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Merck KGaA / Novabiochem&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Undated product page; accessed 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Properties; Description; Application; Related Categories&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Confirms Novabiochem coupling reagents and related peptide-synthesis products.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Catalogue products establish capability, not customers, sales or share.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.merckmillipore.com/LT/en/product/mm/851013" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C02" aria-labelledby="heading-C02"&gt;&lt;h3 id="heading-C02"&gt;[C02] Investor relations activity record 2023-006&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Sunresin / 蓝晓科技&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2023-11-16 (document date; URL uploaded January 2024)&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; PDF p.3, question 3; p.2, question 1&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Discloses peptide solid-phase synthesis resins and chromatography equipment.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Historical 2023 participation, not 2026 revenue or share; no named originator customer.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.sunresin.com/storage/posts/January2024/mF73Dc68wR2JrzNOkJog.PDF" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C03" aria-labelledby="heading-C03"&gt;&lt;h3 id="heading-C03"&gt;[C03] The era of large-scale peptide &amp;amp; oligo purification with MCSGP has begun&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Bachem / YMC-Chromacon&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2024-01-10&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Moving from batch mode to continuous production; How does continuous chromatography or MCSGP work?&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Continuous chromatography recycles side fractions, illustrating purification and solvent-handling bottlenecks.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; One molecule is not a sector-wide benchmark; the article does not adopt its performance percentages.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.bachem.com/knowledge-center/the-era-of-large-scale-peptide-oligo-purification-with-mcsgp-has-begun/" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C04" aria-labelledby="heading-C04"&gt;&lt;h3 id="heading-C04"&gt;[C04] Bachem confirms growth and expects a strong second half 2026&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Bachem&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-07-30&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Group results; Sales by product category; Substantial capacity expansion&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Building K commercial GMP production and ramp-up costs; H1 EBITDA margin 25.4%, versus 29.1% a year earlier.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Group includes oligonucleotides; these are not GLP-1-only financial results.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.bachem.com/articles/news/ad-hoc/bachem-confirms-growth-and-expects-a-strong-second-half-2026/" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C05" aria-labelledby="heading-C05"&gt;&lt;h3 id="heading-C05"&gt;[C05] Half-year Report 2026: Business review&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; PolyPeptide&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-08-13 results release; report covers six months ended 2026-06-30&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Revenue and customer projects; Profitability; Operational progress; Mid-term outlook&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Belgian plant operated at target utilisation; additional assets at other sites remained in commissioning or ramp-up.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Metabolic therapeutics is not identical to GLP-1; target utilisation percentage is undisclosed.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://report.polypeptide.com/hyr/26/business-review" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C06" aria-labelledby="heading-C06"&gt;&lt;h3 id="heading-C06"&gt;[C06] 2026 interim report&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; WuXi AppTec / WuXi TIDES / 药明康德&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-08-04 filing; period ended 2026-06-30&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; PDF pp.11–12, management discussion, WuXi Chemistry / TIDES&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; TIDES includes oligonucleotides and peptides; H1 revenue RMB 7.26 billion.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Not GLP-1 revenue or proof of a named brand supply contract.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://static.cninfo.com.cn/finalpage/2026-08-04/1225455027.PDF" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C09" aria-labelledby="heading-C09"&gt;&lt;h3 id="heading-C09"&gt;[C09] 2026 interim report&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Asymchem / 凯莱英&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-08-25 filing; period ended 2026-06-30&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; PDF pp.10–11, chemical macromolecule CDMO and formulation CDMO&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Chemical macromolecule platform covers peptides, oligonucleotides and toxin-linkers; project stages are disclosed.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Planned reactor volume is not realised output; project counts are not order value.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://static.cninfo.com.cn/finalpage/2026-08-25/1225496302.PDF" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C10" aria-labelledby="heading-C10"&gt;&lt;h3 id="heading-C10"&gt;[C10] Hybio Wuhan Partners with GenTech to Forge New Paths in Peptide Industry Waste Liquid Resource Recovery&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Hybio / 翰宇药业&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-04-25&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Main release paragraphs 1–6&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Wuhan site describes a peptide-manufacturing waste-recovery project.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Company project, not verified realised savings or an industry average.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.hybio.com/news/hybio-wuhan-partners-with-gentech-to-forge-new-paths-in-peptide-industry-waste-liquid-resource-recovery/" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C11" aria-labelledby="heading-C11"&gt;&lt;h3 id="heading-C11"&gt;[C11] Commercial Supply and Peptide CDMO services&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Sinopep-Allsino / 江苏诺泰澳赛诺生物制药股份有限公司 (688076)&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; Undated live corporate page; accessed 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Our Services; Commercial Supply&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Sinopep-Allsino offers peptide API and formulation services.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Company-stated capability, not actual GLP-1 output; do not confuse with Chengdu Shengnuo.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.sinopep.com/" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C12" aria-labelledby="heading-C12"&gt;&lt;h3 id="heading-C12"&gt;[C12] CordenPharma Expands Peptide Platform with &amp;gt;€500 m Greenfield Facility Construction in the Basel Region of Switzerland&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; CordenPharma&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2025-03-05&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Investment overview; Muttenz and Colorado capacity plans&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Announces European and US peptide-platform expansion plans.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Planned commercial starts such as 2028 are not operating 2026 supply.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://cordenpharma.com/articles/press-release-cordenpharma-expands-peptide-platform-with-more-than-500-million-euro-greenfield-facility-construction-near-basel-switzerland/" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C07" aria-labelledby="heading-C07"&gt;&lt;h3 id="heading-C07"&gt;[C07] End-to-end offering for Molly autoinjectors at Thermo Fisher&amp;#x27;s Ridgefield, New Jersey site&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; SHL Medical / Thermo Fisher Scientific&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-03-19&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; Company-specific activity; periods as dated&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Press release main text&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; SHL and Thermo Fisher collaborate on filling, autoinjector assembly and packaging.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Not a disclosed GLP-1 brand contract or delivered output.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary company disclosure&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.shl-medical.com/news-insights/news/end-to-end-offering-molly-autoinjectors-thermo-fisher-ridgefield-new-jersey-site" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;section class="research-evidence" id="source-C08" aria-labelledby="heading-C08"&gt;&lt;h3 id="heading-C08"&gt;[C08] Financial report for 1 January–31 March 2026&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Publisher:&lt;/strong&gt; Novo Nordisk&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Date:&lt;/strong&gt; 2026-05-06&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Period / scope:&lt;/strong&gt; China exclusivity litigation; India formulation litigation&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Location:&lt;/strong&gt; Legal matters, p.20&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Supports:&lt;/strong&gt; Discloses Chinese exclusivity and other patent disputes; expiry is not guaranteed freedom to launch.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Limits:&lt;/strong&gt; Litigation allegations are not final court findings; verify rights, jurisdiction and date.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Evidence type:&lt;/strong&gt; Primary record&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Accessed:&lt;/strong&gt; 2026-10-21&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Original sources:&lt;/strong&gt; &lt;a href="https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm" target="_blank" rel="noopener"&gt;Source 1&lt;/a&gt;&lt;/p&gt;&lt;/section&gt;
&lt;p class="research-figure-caption"&gt;Presentation references: &lt;a href="https://thedexs.com/post/cybersecurity-industry-report/"&gt;Cybersecurity industry report&lt;/a&gt; and &lt;a href="https://thedexs.com/post/drone-networks/"&gt;Drone networks report&lt;/a&gt;. These inform presentation, not industry facts.&lt;/p&gt;</description></item></channel></rss>